Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bright Minds Biosciences Inc. (DRUG : NSDQ)

• Company Description    Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $25.93 Daily Weekly Monthly 20 Day Moving Average: 59,087 shares Shares Outstanding: 7.04 (millions) Market Capitalization: $182.65 (millions) Beta: -6.01 52 Week High: $79.02 52 Week Low: $0.94 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.63% -12.05% 12 Week -21.68% -34.13% Year To Date -28.01% -32.58%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 19 VESTRY STREET - NEW YORK,NY 10013 USA ph: 64-7407-2515 fax: - None http://www.brightmindsbio.com

• General Corporate Information    Officers Ian McDonald - President; Chief Executive Officer and Director Ryan Cheung - Chief Financial Officer Nils Christian Bottler - Director Jeremy Fryzuk - Director Jan Pedersen - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10919W405 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 7.04 Most Recent Split Date: 7.00 (0.20:1) Beta: -6.01 Market Capitalization: $182.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.70 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.78 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -190.00% vs. Previous Quarter: -3,000.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -14.56 12/31/24 - -5.85 ROA 06/30/25 - - 03/31/25 - -14.29 12/31/24 - -5.68 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 126.01 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 126.01 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 9.31 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.19

Powered by Zacks Investment Research ©